	US 12,084,504 B2
	Anti-MET antibodies and uses thereof
Paolo Michieli, Rivalta di Torino (IT)
Assigned to AGOMAB THERAPEUTICS, Ghent (BE)
Filed by AGOMAB THERAPEUTICS, Ghent (BE)
Filed on Aug. 9, 2021, as Appl. No. 17/397,510.
Application 17/397,510 is a division of application No. 16/313,710, granted, now 11,098,126, previously published as PCT/EP2017/065599, filed on Jun. 23, 2017.
Claims priority of application No. 1611123 (GB), filed on Jun. 27, 2016.
Prior Publication US 2022/0153850 A1, May 19, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01); A61P 13/12 (2006.01); A61P 29/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61P 1/04 (2018.01); A61P 1/16 (2018.01); A61P 3/10 (2018.01); A61P 13/12 (2018.01); A61P 29/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

12 Claims

1. A method of treating a condition selected from the group consisting of liver damage, kidney damage, inflammatory bowel disease, diabetes, and non-alcoholic steatohepatitis in a subject suffering therefrom, or promoting wound healing in a subject, the method comprising:

administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment;

wherein the antibody or antigen binding fragment binds human MET protein comprising the amino acid sequence of SEQ ID NO: 239;

wherein the antibody or antigen binding fragment comprises:

a heavy chain variable domain comprising H-CDR1, H-CDR2 and H-CDR3, and

a light chain variable domain comprising L-CDR1, L-CDR2 and L-CDR3, and

wherein:

H-CDR1 comprises the amino acid sequence of SEQ ID NO:30,

H-CDR2 comprises the amino acid sequence of SEQ ID NO:32,

H-CDR3 comprises the amino acid sequence of SEQ ID NO:34,

L-CDR1 comprises the amino acid sequence of as SEQ ID NO: 107,

L-CDR2 comprises the amino acid sequence of as SEQ ID NO: 109, and

L-CDR3 comprises the amino acid sequence of SEQ ID NO: 111;

H-CDR1 comprises the amino acid sequence of SEQ ID NO: 65,

H-CDR2 comprises the amino acid sequence of SEQ ID NO: 67,

H-CDR3 comprises the amino acid sequence of SEQ ID NO: 69,

L-CDR1 comprises the amino acid sequence of as SEQ ID NO: 142,

L-CDR2 comprises the amino acid sequence of as SEQ ID NO: 144, and

L-CDR3 comprises the amino acid sequence of SEQ ID NO: 146;

H-CDR1 comprises the amino acid sequence of SEQ ID NO: 2,

H-CDR2 comprises the amino acid sequence of SEQ ID NO: 4,

H-CDR3 comprises the amino acid sequence of SEQ ID NO: 6,

L-CDR1 comprises the amino acid sequence of as SEQ ID NO: 79,

L-CDR2 comprises the amino acid sequence of as SEQ ID NO: 81, and

L-CDR3 comprises the amino acid sequence of SEQ ID NO: 83.